New research indicates that individuals living with dementia are being treated with potent antipsychotic medications for ...

People with dementia are being treated with powerful antipsychotic medications for longer than guidelines recommend, ...

A multicenter collaboration of Danish researchers reports that once-weekly semaglutide for 30 weeks lowered blood sugar ...

The high prevalence of addiction — and the department’s struggle to keep prescribed and illicit drug use under control — has ...

The number of overdoses reflects the challenge facing the DOC: keeping illegal drugs out of CT prisons and treating addiction ...

Bristol Myers Squibb (BMS) plans to launch schizophrenia drug Cobenfy in the UK next year at a price matching its U.S. list ...

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDS ...

This study highlights how antipsychotic prescribing in dementia is discordant with current NICE guidelines on both duration ...

An investigational drug did not significantly improve outcomes versus quetiapine extended release (Seroquel XR) as an ...

“When combined with stimulant medications, there can be an additive effect, leading to elevated heart rate, increased blood ...

One of the nation's largest drug advertisers is likely working up major changes to its ad strategy in the wake of a federal government crackdown on drug TV commercials.

Bristol said it planned to submit a marketing authorisation application for Cobenfy to the UK medicines regulator later this ...